Project Grant R01AG087633
Award Date 8/15/26
Completion Date 5/31/31
Dollars Obligated $656K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Tempe, AZ 85287, USA
Similar Awards
- The National Institute on Aging awarded a $7.287 million cooperative agreement to Arizona State University on September 1, 2026, under the Aging Research program (CFDA 93.866). The award funds a five-year research initiative running through August 31, 2031, examining heterogeneity in aging using a free-ranging rhesus macaque population on Cayo Santiago Island, Puerto Rico—the world's longest-running primate field station. The research program addresses three integrated questions: quantifying how...
- The National Institute on Aging awarded Arizona State University $431,750 under the Aging Research program (CFDA 93.866) on September 1, 2026, to define the mechanisms underlying the protective effects of the RELN-COLBOS variant in Alzheimer's disease. The funded research leverages stem cell bioengineering, genome editing, and neurodegenerative disease modeling to elucidate the neuroprotective mechanisms of the RELN-COLBOS variant, a rare Reelin variant identified in a PSEN1 mutation carrier...
- The National Institute on Aging awarded Arizona State University $675,329 on May 1, 2026, under the Aging Research program (CFDA 93.866) to characterize cellular pathology and biomarkers in an Alzheimer's disease model developed through gene delivery in aged macaque monkeys. The research extends prior work conducted under a companion R24 grant in which the investigators developed a tauopathy model by injecting an adeno-associated virus carrying an aggregation-prone human tau variant...
- The National Institute on Aging awarded Arizona State University $484,575 on September 1, 2026, under the Aging Research program (CFDA 93.866) to evaluate the impact of dietary choline on cognitive decline and Alzheimer's disease biomarkers in rural populations, particularly in Arizona where AD incidence is elevated and elder adults in geographically isolated communities face significantly higher risks of cognitive decline yet remain drastically understudied. The project will investigate...
- The National Institute on Aging awarded the University of Arizona $396,241 on September 1, 2026, under the Aging Research program (CFDA 93.866) to conduct a longitudinal, multi-modal study tracking neuroplasticity changes in preclinical and prodromal Alzheimer's disease stages using transcranial magnetic stimulation (TMS) integrated with blood and MRI biomarkers. The study employs TMS to assess non-invasive, repeatable neurophysiological measures of neuroplasticity and correlates these...
- The National Institute on Aging awarded New York University $6.203 million on September 15, 2025, under the Aging Research program (CFDA 93.866) to examine peripheral immune markers and vascular dysfunction as contributors to cognitive decline and Alzheimer's disease. The research integrates circulating biomarkers—platelet aggregation, neutrophil activity, and proteomic data—with advanced imaging to assess associations between vascular and immune dysfunction and cerebrovascular burden, amyloid...
- The National Institute on Aging awarded Arizona State University $1,249,351 on September 1, 2026, under the Aging Research program (CFDA 93.866) to examine day-to-day fluctuations in loneliness and their relationship to biological and functional aging outcomes across multiple timescales. The research will identify patterns of daily loneliness—average daily loneliness, loneliness volatility (day-to-day fluctuations), and loneliness reactivity to daily triggers—and map how these patterns predict...
- The National Institute on Aging awarded the University of Arizona $996,193 on July 15, 2026, under the Aging Research program (CFDA 93.866) to evaluate how small and large vessel cerebrovascular disease interact over time to contribute to Alzheimer's disease and related dementias risk. The project will examine how extracranial large vessels, intracranial large vessels, and cerebral small vessels interact across different patient populations, with particular attention to sex-specific...
- The National Institute on Aging awarded the University of Alabama at Birmingham $405,955 on June 1, 2026, under the Aging Research program (CFDA 93.866) to develop and validate two novel retinal biomarkers for early Alzheimer's disease detection: retinal mid-peripheral capillary free zones and putative retinal gliosis. The award supports quantification and validation of these biomarkers using optical coherence tomography angiography and spectral domain OCT imaging, with the goal of providing a...
- The National Institute on Aging awarded the University of Arizona $611,338 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop selective DYRK1A inhibitors for Alzheimer's disease treatment. The research targets dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) as a therapeutic intervention modulating tau, amyloid, and neuroinflammatory pathways in Alzheimer's disease. Prior work demonstrated that the DYRK1A inhibitor DYR533 improves behavioral and...